Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm

Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.